Drone strikes attacked an oil processing facility at Abqaiq and the nearby Khurais oil field on Saturday.Marketsread more
Trump said oil would be released if needed to keep the market well supplied and he would expedite the approval of pipelines in Texas and other states.Marketsread more
Saudi Aramco is aiming to restore by Monday about a third of its crude output that was disrupted after drone attacks on two key oil facilities, The Wall Street Journal...Marketsread more
Apple's new iPhones can still send texts, download apps, and make video calls, but the company spends a lot of time and effort marketing its new phones as powerful photography...Technologyread more
The trucking industry is worth hundreds of billions of dollars per year. Uber is going after this market with Uber Freight, an online platform that matches truckers with...Technologyread more
Some U.S. manufacturers say tariffs, if targeted, will help address longstanding unfair trade practices like intellectual property theft.Traderead more
Supporters of a $15 minimum wage ballot initiative in Florida argue the state's inflation-tied pay hikes have not gone far enough.2020 Electionsread more
Saudi Arabia shut down half its oil production Saturday after drone strikes hit the world's largest oil processing facility in an attack claimed by Yemen's Houthi rebels.Politicsread more
Trusii's hydrogen water machines were supposed to help users with their health problems, but customers claim the company is involved in a giant scam.Technologyread more
The decoupling of the world's two weightiest economies seems as inescapable as its extent and global impact remains incalculable.Politicsread more
BlackBerry has reinvented itself to become a leader in securing mobile communications and in embedded communications. Next year it plans to roll out new products. CEO John...Evolveread more
Roche on Thursday confirmed its full-year 2016 outlook on the strength of robust sales of cancer drugs including Tecentriq, the new immunotherapy that the Swiss company is banking on to counter patent expirations of its older medicines.
Third-quarter sales at the world's biggest maker of cancer drugs rose to 12.48 billion Swiss francs ($12.61 billion) from 11.9 billion francs in the same period in 2015, it said.
Analysts polled by Reuters had on average expected sales of 12.68 billion francs.
Roche said all of its recently launched medicines had performed well, with Tecentriq bringing in 77 million francs since its approval in May for bladder cancer. That revenue is now due to accelerate after U.S. regulators this week gave the drug a green light to be used against lung cancer.
"Tecentriq has been performing strongly since May," Chief Executive Severin Schwan said in the statement. "Based on our performance so far, I am confident that we will meet our full-year targets for 2016."
Schwan, who aims for Tecentriq to muscle in on territory now dominated by immunotherapy drugs from Bristol-Myers Squibb and Merck & Co, expects Roche's 2016 sales to grow by a low- to mid-single digit percentage rate at constant exchange rates, with core earnings growing faster than sales.
The company plans to boost its dividend in Swiss francs.
Nine-month sales rose 4 percent at constant exchange rates to 37.5 billion francs, shy of the average analyst estimate of 37.7 billion francs in a Reuters poll.